

Evalveerimine 2010 Application EV32 Competence Center for Cancer Research, Health

Expert's opinion: The volume and level of R&D activities in comparison to international criteria.

Subcriteria for evaluation	Evaluation	Comments
The research and development in the field being evaluated is characterized by a sufficient volume of financing taking into account the particularities of the field of research and the profile of the institution.	Positive	Going into Phase I and II Clinical trials is very expensive and funds available do not map onto this goal at this stage.
Research and development at the institution is characterized by contemporary and innovative range of topics for research.	Positive	The enormous range of projects collected and cited gives major concern of a need for focus and critical mass building. Ideas in drug discovery and subsequent development are naive at this stage, given the experience that we were presented with (no real evidence of active collaboration with drug design teams or clinicians was evident on the visit).
The institution has international cooperation projects in the field being evaluated and/or participates in various international cooperation networks.	Positive	
Experts' summary assessment	Positive	see comments above

Expert's opinion: R&D infrastructure (working premises and auxiliary facilities).


Subcriteria for evaluation	Evaluation	Comments
The institution's research groups in the field being evaluated have at their disposal the necessary working and auxiliary facilities (premises).	Positive	
The working facilities (premises) at the disposal of the institution's research groups in the field being evaluated are modern and fit for purpose.	Positive	
The institution's research groups in the field being evaluated have at their disposal, in the case of experimental themes, the necessary equipment and instruments.	Positive	
The equipment and instruments at the disposal of the institution's research groups in the field being evaluated are, in the case of the experimental themes, modern and fit for purpose.	Positive	
The institution's research groups in the field being evaluated have access to databases, specialized literature and other research infrastructures.	Positive	
Experts' summary assessment	Positive	


Expert's opinion: Qualification of researchers in comparison to international criteria.


Subcriteria for evaluation	Evaluation	Comments
A sufficient number of research staff are employed at the institution taking into account the volume and particularities of the R&D activities of the institution and the field being evaluated.	Positive	
A sufficient number of the research staff have a recognized academic degree corresponding to Estonian legislative acts.	Positive	


Doctoral dissertations have been successfully supervised in the last five years.	Positive	Only 4 in total cited, which is really low for such a large association of staff as named in the Centre.
Research staff in the field being evaluated have received sufficient national or international honours and/or awards.	Positive	
Research staff have published per researcher in the last 5 years a sufficient number of articles in international journals or peer-reviewed research monographs taking into account the particularities of the field of research being evaluated.	Positive	Very low rate of publications averaged overall. Most strong papers are associated with only a small number of PIs.
Research staff have filed applications for patents or for plant variety rights certificates in the name of the institution in the last 5 years.	Positive	183 patents for 14 PIs is huge - how can it be paid for sustainably?
Experts' summary assessment	Positive	
Subcriteria for evaluation	Evaluation	Comments
Final assessment	Positive	The enormous range of projects collected and cited gives major concern of a need for focus and critical mass building. Ideas in drug discovery and subsequent development are naive at this stage, given the experience that we were presented with (no real evidence of active collaboration with drug design teams or clinicians was evident on the visit). Going into Phase I and II Clinical trials is very expensive and funds available do not map onto this goal at this stage.

Confirmed 20.05.2010


 Roland Axtmann
 Chairperson of the evaluation committee;
 spokesperson of the subcommittee „Culture and Society“


 Hans Brix,
 Spokesperson of the subcommittee
 „Biosciences and Environmental Sciences“


 Kenneth Douglas,
 spokesperson of the subcommittee „Health“


 Eric Gregoire,
 spokesperson of the Subcommittee
 „Natural Sciences and Engineering“